vs
Side-by-side financial comparison of UNIVERSAL DISPLAY CORP \PA\ (OLED) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $172.9M, roughly 1.1× UNIVERSAL DISPLAY CORP \PA\). On growth, UNIVERSAL DISPLAY CORP \PA\ posted the faster year-over-year revenue change (6.6% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $15.1M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 2.3%).
Universal Display Corporation is a developer and manufacturer of organic light emitting diode (OLED) technologies and materials, and it is a provider of services to the display and lighting industries.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
OLED vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $172.9M | $196.9M |
| Net Profit | $66.3M | — |
| Gross Margin | 76.1% | 79.5% |
| Operating Margin | 38.9% | 1.2% |
| Net Margin | 38.4% | — |
| Revenue YoY | 6.6% | 5.1% |
| Net Profit YoY | 44.2% | — |
| EPS (diluted) | $1.40 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $172.9M | $196.9M | ||
| Q3 25 | $139.6M | $179.5M | ||
| Q2 25 | $171.8M | $181.1M | ||
| Q1 25 | $166.3M | $168.9M | ||
| Q4 24 | $162.3M | $187.3M | ||
| Q3 24 | $161.6M | $168.6M | ||
| Q2 24 | $158.5M | $178.0M | ||
| Q1 24 | $165.3M | $167.1M |
| Q4 25 | $66.3M | — | ||
| Q3 25 | $44.0M | $5.4M | ||
| Q2 25 | $67.3M | $-4.8M | ||
| Q1 25 | $64.4M | $4.8M | ||
| Q4 24 | $46.0M | — | ||
| Q3 24 | $66.9M | $-143.5M | ||
| Q2 24 | $52.3M | $18.9M | ||
| Q1 24 | $56.9M | $9.0M |
| Q4 25 | 76.1% | 79.5% | ||
| Q3 25 | 74.6% | 80.9% | ||
| Q2 25 | 77.2% | 77.4% | ||
| Q1 25 | 77.1% | 79.7% | ||
| Q4 24 | 77.0% | 78.7% | ||
| Q3 24 | 77.8% | 76.9% | ||
| Q2 24 | 75.8% | 75.1% | ||
| Q1 24 | 77.6% | 71.6% |
| Q4 25 | 38.9% | 1.2% | ||
| Q3 25 | 30.9% | 3.5% | ||
| Q2 25 | 39.9% | 4.7% | ||
| Q1 25 | 41.9% | 1.2% | ||
| Q4 24 | 32.3% | 13.2% | ||
| Q3 24 | 41.5% | -82.8% | ||
| Q2 24 | 35.6% | 15.9% | ||
| Q1 24 | 38.0% | 7.9% |
| Q4 25 | 38.4% | — | ||
| Q3 25 | 31.5% | 3.0% | ||
| Q2 25 | 39.2% | -2.7% | ||
| Q1 25 | 38.8% | 2.8% | ||
| Q4 24 | 28.4% | — | ||
| Q3 24 | 41.4% | -85.1% | ||
| Q2 24 | 33.0% | 10.6% | ||
| Q1 24 | 34.4% | 5.4% |
| Q4 25 | $1.40 | $0.05 | ||
| Q3 25 | $0.92 | $0.12 | ||
| Q2 25 | $1.41 | $-0.11 | ||
| Q1 25 | $1.35 | $0.10 | ||
| Q4 24 | $0.96 | $0.38 | ||
| Q3 24 | $1.40 | $-3.11 | ||
| Q2 24 | $1.10 | $0.39 | ||
| Q1 24 | $1.19 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $602.4M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $1.8B | $693.1M |
| Total Assets | $2.0B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $602.4M | $238.4M | ||
| Q3 25 | $603.0M | $246.3M | ||
| Q2 25 | $525.2M | $445.9M | ||
| Q1 25 | $571.3M | $493.6M | ||
| Q4 24 | $492.7M | $484.6M | ||
| Q3 24 | $551.6M | $453.8M | ||
| Q2 24 | $530.5M | $404.2M | ||
| Q1 24 | $539.3M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.8B | $693.1M | ||
| Q3 25 | $1.7B | $727.2M | ||
| Q2 25 | $1.7B | $757.8M | ||
| Q1 25 | $1.7B | $798.5M | ||
| Q4 24 | $1.6B | $778.3M | ||
| Q3 24 | $1.6B | $749.6M | ||
| Q2 24 | $1.5B | $879.3M | ||
| Q1 24 | $1.5B | $892.2M |
| Q4 25 | $2.0B | $1.3B | ||
| Q3 25 | $1.9B | $1.3B | ||
| Q2 25 | $1.9B | $1.5B | ||
| Q1 25 | $1.9B | $1.6B | ||
| Q4 24 | $1.8B | $1.6B | ||
| Q3 24 | $1.8B | $1.5B | ||
| Q2 24 | $1.8B | $1.6B | ||
| Q1 24 | $1.7B | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.1M | $43.7M |
| Free Cash FlowOCF − Capex | $15.1M | $43.5M |
| FCF MarginFCF / Revenue | 8.7% | 22.1% |
| Capex IntensityCapex / Revenue | 9.3% | 0.1% |
| Cash ConversionOCF / Net Profit | 0.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $154.4M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.1M | $43.7M | ||
| Q3 25 | $97.2M | $60.8M | ||
| Q2 25 | $51.9M | $12.0M | ||
| Q1 25 | $30.6M | $35.5M | ||
| Q4 24 | $34.7M | $33.1M | ||
| Q3 24 | $79.9M | $53.9M | ||
| Q2 24 | $67.0M | $53.2M | ||
| Q1 24 | $72.2M | $49.1M |
| Q4 25 | $15.1M | $43.5M | ||
| Q3 25 | $84.3M | $57.0M | ||
| Q2 25 | $37.5M | $9.3M | ||
| Q1 25 | $17.5M | $26.9M | ||
| Q4 24 | $22.0M | $31.0M | ||
| Q3 24 | $66.2M | $49.8M | ||
| Q2 24 | $57.9M | $51.6M | ||
| Q1 24 | $65.0M | $46.3M |
| Q4 25 | 8.7% | 22.1% | ||
| Q3 25 | 60.4% | 31.7% | ||
| Q2 25 | 21.8% | 5.1% | ||
| Q1 25 | 10.5% | 15.9% | ||
| Q4 24 | 13.6% | 16.6% | ||
| Q3 24 | 41.0% | 29.6% | ||
| Q2 24 | 36.5% | 29.0% | ||
| Q1 24 | 39.3% | 27.7% |
| Q4 25 | 9.3% | 0.1% | ||
| Q3 25 | 9.2% | 2.2% | ||
| Q2 25 | 8.4% | 1.5% | ||
| Q1 25 | 7.9% | 5.1% | ||
| Q4 24 | 7.8% | 1.1% | ||
| Q3 24 | 8.4% | 2.4% | ||
| Q2 24 | 5.8% | 0.9% | ||
| Q1 24 | 4.4% | 1.7% |
| Q4 25 | 0.47× | — | ||
| Q3 25 | 2.21× | 11.20× | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.47× | 7.37× | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | 1.19× | — | ||
| Q2 24 | 1.28× | 2.82× | ||
| Q1 24 | 1.27× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OLED
| Material Sales | $95.5M | 55% |
| Other | $72.6M | 42% |
| Contract Research Services | $4.8M | 3% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
